Treatment of Drug-Induced Liver Injury Due to TB Therapy
When AST/ALT rises to 5× upper limit of normal or bilirubin becomes elevated, immediately stop rifampicin, isoniazid, and pyrazinamide 1.
Immediate Management Algorithm
Step 1: Stop Hepatotoxic Drugs
- Discontinue rifampicin, isoniazid, and pyrazinamide immediately when liver injury is confirmed 1.
- The threshold for stopping is AST/ALT ≥5× ULN or any elevation in bilirubin 1.
Step 2: Determine Need for Continued TB Treatment
For non-infectious TB in stable patients:
- No treatment is needed until liver function normalizes 1.
- Monitor clinically and biochemically.
For infectious TB (sputum smear-positive) or unwell patients:
- Continue treatment with streptomycin and ethambutol as inpatient until liver function normalizes 1.
- These drugs have minimal hepatotoxicity and maintain TB treatment efficacy.
- Ensure appropriate renal monitoring for streptomycin use.
Step 3: Sequential Drug Reintroduction Protocol
Once liver function returns to normal, reintroduce drugs one at a time in this specific order with daily clinical and biochemical monitoring 1:
Isoniazid first:
- Start 50 mg/day
- Increase to 300 mg/day after 2-3 days if no reaction
- Continue for 2-3 days before adding next drug
Rifampicin second:
- Start 75 mg/day
- Increase to 300 mg after 2-3 days
- Then increase to 450 mg (<50 kg) or 600 mg (>50 kg) after another 2-3 days
- Continue for 2-3 days before adding next drug
Pyrazinamide last:
- Start 250 mg/day
- Increase to 1.0 g after 2-3 days
- Then increase to 1.5 g (<50 kg) or 2.0 g (>50 kg)
Step 4: If Rechallenge Fails
If hepatotoxicity recurs:
- Identify and permanently exclude the offending drug 1.
- Consult a TB specialist for alternative regimen design.
If pyrazinamide is the culprit:
- Continue rifampicin and isoniazid for 9 months total
- Add ethambutol for initial 2 months 1.
If multiple drugs cannot be reintroduced:
- Consider alternative regimens with fluoroquinolones, ethambutol, and second-line agents 2.
- Treatment duration may extend to 18-24 months depending on drug resistance patterns.
Monitoring During Reintroduction
- Daily monitoring of clinical condition and liver function tests during rechallenge 1.
- Stop immediately if AST/ALT rises above 5× ULN or bilirubin elevates.
- Consider virological testing to exclude concurrent viral hepatitis 1.
Important Caveats
Recent evidence suggests more aggressive thresholds may be safe: A 2026 randomized trial found that continuing all drugs unless ALT ≥10× ULN (rather than 5× ULN) appeared safe and reduced treatment interruptions 3. However, the established guideline threshold of 5× ULN remains the standard recommendation 1.
Hepatoprotective drugs: While not routinely recommended by older guidelines 1, recent evidence suggests preventive hepatoprotective agents (particularly bicyclol, magnesium isoglycyrrhizinate, or silymarin) may reduce DILI risk in high-risk patients 4, 5, 6, 7. Consider these for patients with baseline liver disease, though they should not replace careful monitoring.
Severe liver injury: For acute liver failure, consider N-acetylcysteine early, artificial liver support, or emergency liver transplantation 4, 8. These patients require immediate intensive care and hepatology consultation.
Desensitization: In cases of drug-resistant TB where options are severely limited, desensitization protocols may be necessary, but must be done under cover of two other effective anti-TB drugs to prevent resistance emergence 1.